Overall verdict
Sell
3.0/10
1-year performance
-20.12%
Score breakdown
Down 20.1% over 1 year, 13% of the 52-week range.
Strongest: Financial strength 7.5/10. Weakest: Shareholder return 0.0/10.
16 analysts.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy ;
VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma ; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.
It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Sector
Health Care
Industry
Biotechnology
Primary listing
Amex
United States
CEO
Johan Spoor
Founded
1983
Employees
166
Revenue / employee
5 325 USD
Next earnings
November 9, 2026 (estimated)
Institutional holders
- BlackRock, Inc.7.97%
- TCG Crossover Management, LLC6.65%
- Commodore Capital LP5.32%
- Avidity Partners Management LP5.29%
- STATE STREET CORP5.08%
- MILLENNIUM MANAGEMENT LLC4.12%
- VANGUARD CAPITAL MANAGEMENT LLC3.72%
- Affinity Asset Advisors, LLC3.54%
- CITADEL ADVISORS LLC3.20%
- Other institutions27.46%
- Rest of the register27.65%
130 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
6.16 USD
52-week low
1.96 USD
1-year performance
-20.12%
Declining
Year-to-date performance
-4.73%
Declining
Drawdown
-59.24%
Major drawdown
Position in the 52-week range
13% of range
Gross margin -891.0%, the company loses 28516.1% of its revenue, ROIC -39.2%, ROE -39.6%.
Net margin
-28516.14%
Negative
Sector -229.11%|S&P 12.97%
Gross margin
-890.95%
Negative
Return on equity (ROE)
-39.57%
Negative
Sector -58.37%|S&P 16.52%
Return on invested capital (ROIC)
-39.20%
Negative
Free cash flow margin (FCF)
-29663.08%
Negative
Margin stability
3640.3 pts
Very uneven
Growth
0.0/10Revenue down 72.1% over 1 year, -38.0% a year over 5.
Revenue (trailing 12 months)
409 000 USD
Revenue growth (1y)
-72.07%
Declining
Revenue growth (3y)
-91.81%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 1.76|S&P 0.86
Market cap
299M USD
Financial strength
7.5/10Cash covers 5977.2% of the debt, net debt/EBITDA 0.4x.
Net debt / EBITDA
0.4x
Very solid
Gearing (net debt / equity)
-71.92%
Net cash
Cash
237M USD
Cash / market cap
79.20%
Very solid
Cash / total debt
5977.19%
Net cash
Interest coverage
-1490.9x
Stretched
Net debt
-233M USD
Equity
324M USD
Closed daily candles, 23 months
Last close on September 4, 2026: 3.13 USD
- MM203.18
- MM503.14
- MM2003.57
- RSI 1449.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.83%
200-day average slope, 3 months
-1.46%
50-day average slope, 1 month
-0.76%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
3.63 % per day
Volatility change
-7.95%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.00 (16) | -0.98 (10) | 0 (14) | -125 (2) | -114 (13) |
| 2027 | -1.05 (13) | -1.01 (7) | 0 (13) | -139 (2) | -135 (12) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 18, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 4 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 5 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 6 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 7 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 8 | CATX | 3.0 | 1.1 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 0.4x | -40.6 % | -20.1 % | ||
| 9 | A174900 | 2.1 | 2.2 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.1 % | 27.3 % |
